Table 4 Summary of ESMO-MCBS for RCC therapeutics
Treatment | Form | Hazard Ratioa | Survival gaina (months) | Preliminary clinical benefit grade | Early stopping or crossover a | Toxicity improvement | Quality of Life improvement | Final Grade |
|---|---|---|---|---|---|---|---|---|
Pazopanib | 2c | 4 | + | + | 4 | |||
Nivolumab + Ipilimumab | 2a (>24mo) | 0.44 (OS) | > 9 (15.2) | 4 | + | – | 5 | |
Axitinib + Avelumab | 2b (>6mo) | 0.56 (PFS) | 5.4 | 3 | – | – | NA | 3 |
Axitinib + Pembrolizumab | 2b (>6mo) | 0.57 (PFS) | 4 | 3 | – | – | NA | 3 |
Lenvatinib+Pembrolizumab | 2b (>6mo) | 0.39 (PFS) | 14.7 | 3 | + | – | NA | 4 |
Cabozantinib+Nivolumab | 2b (>6mo) | 0.41 (PFS) | 8.3 | 3 | + | – | – | 4 |